Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Conditions
Interventions
ANG1005
Bevacizumab
Locations
12
United States
Moores UC San Diego Cancer Center
La Jolla, California, United States
Northwestern University
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States
Start Date
October 1, 2013
Primary Completion Date
February 1, 2016
Completion Date
September 1, 2017
Last Updated
February 25, 2020
NCT07539441
NCT03206060
NCT04065776
NCT03050268
NCT05636618
NCT05099003
Lead Sponsor
Angiochem Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions